These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31669513)

  • 21. Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.
    Laubach JP; Paba Prada CE; Richardson PG; Longo DL
    Clin Pharmacol Ther; 2017 Jan; 101(1):81-88. PubMed ID: 27806428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating the HYDRASHIFT 2/4 Daratumumab assay: a powerful approach to assess treatment response in multiple myeloma.
    Lee HW; Kim SM; Park HD
    Clin Chem Lab Med; 2024 Oct; 62(11):2223-2232. PubMed ID: 38630027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
    Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
    Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging antibodies for the treatment of multiple myeloma.
    Zagouri F; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):225-37. PubMed ID: 27195659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Daratumumab for the Treatment of Multiple Myeloma.
    Plesner T; Krejcik J
    Front Immunol; 2018; 9():1228. PubMed ID: 29915586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative assessment of daratumumab in serum
    Canil G; Miolo G; Simula M; Rupolo M; Steffan A; Corona G
    Anal Methods; 2024 Jul; 16(26):4240-4246. PubMed ID: 38780038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma.
    Offidani M; Corvatta L
    Future Oncol; 2018 Feb; 14(4):319-329. PubMed ID: 29091475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of Daratumumab and Elotuzumab Migration by Capillary Electrophoresis Relative to Transferrin Improves Precision of Their Identification.
    Huls F; Schroeder L; Keren DF
    J Appl Lab Med; 2020 Mar; 5(2):419-422. PubMed ID: 32445376
    [No Abstract]   [Full Text] [Related]  

  • 29. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances and practical use of monoclonal antibodies in multiple myeloma therapy.
    Lee HC; Weber DM
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):512-520. PubMed ID: 27913523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update.
    Abramson HN
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites.
    Chehab S; Zhang C; Panjic EH; Chen Z; Kaufman JL; Lonial S; Nooka A; Harvey RD
    Cancer; 2018 Nov; 124(22):4358-4365. PubMed ID: 30303526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three new drugs for multiple myeloma.
    Med Lett Drugs Ther; 2016 May; 58(1495):e70-1. PubMed ID: 27192621
    [No Abstract]   [Full Text] [Related]  

  • 35. Development and Validation of Electrochemiluminescence Assays to Measure Free and Total sSLAMF7 in Human Serum in the Absence and Presence of Elotuzumab.
    Postelnek J; Neely RJ; Robbins MD; Gleason CR; Peterson JE; Piccoli SP
    AAPS J; 2016 Jul; 18(4):989-99. PubMed ID: 27116021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
    Campbell KS; Cohen AD; Pazina T
    Front Immunol; 2018; 9():2551. PubMed ID: 30455698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-Throughput Therapeutic Antibody Interference-Free High-Resolution Mass Spectrometry Assay for Monitoring M-Proteins in Multiple Myeloma.
    Santockyte R; Puig O; Zheng N; Ouyang Z; Titsch C; Zhang YJ; Pillutla R; Zeng J
    Anal Chem; 2021 Jan; 93(2):834-842. PubMed ID: 33300779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of observed interference by therapeutic monoclonal antibodies in select commonly utilized immunoassays.
    Galior KD; Ladwig PM; Snyder MR; Algeciras-Schimnich A; Bornhorst JA; Block DR; Baumann NA; Willrich MAV
    Clin Biochem; 2023 Nov; 121-122():110685. PubMed ID: 37972806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunopathogenesis and appropriate use of monoclonal antibody agents in multiple myeloma].
    Tamura H
    Rinsho Ketsueki; 2018; 59(10):2169-2177. PubMed ID: 30305523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal antibody utilization characteristics in patients with multiple myeloma.
    Ailawadhi S; Sher T; Azzouqa AG; Meghji Z; Jain T; Jani P; Ahmed S; Diehl N; Roy V; Shah V; Hodge D; Ailawadhi M; Alegria VR; Paulus A; Chanan-Khan A; Fonseca R
    Anticancer Drugs; 2019 Sep; 30(8):859-865. PubMed ID: 31415286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.